--- title: "Immuron (IMC) news: offering" url: "https://aibio.space/companies/immuron/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "IMC offering news: Immuron to issue 45,472,000 shares at AUD 0.07910 in placement. Immuron Limited (ASX: IMC), Australia." --- IMC Immuron Limited ASX · Australia # Immuron (IMC) news IMC offering news Financings · 2025-12-04 ## [Immuron to issue 45,472,000 shares at AUD 0.07910 in placement](https://aibio.space/news/immuron-issue-45-472-000-shares-aud-0-07910-placement/) The 45,472,000 shares are sold to US investors through the company's at-the-market facility, according to a note in the filing. The filing names no lead manager or underwriter. ## Latest Immuron news We have not published a story on Immuron yet. When there is news, it will appear here. ## Immuron at a glance - **Ticker**: IMC - **Listing**: ASX - **Country**: Australia ### Related companies - [Tissue Repair](https://aibio.space/companies/tissue-repair/) ASX: TRP - [Dimerix](https://aibio.space/companies/dimerix/) ASX: DXB - [Sigma Healthcare](https://aibio.space/companies/sigma-healthcare/) ASX: SIG - [Neurizon Therapeutics](https://aibio.space/companies/neurizon-therapeutics/) ASX: NUZ - [Gelteq](https://aibio.space/companies/gelteq/) NASDAQ: GELS - [Medical Developments International](https://aibio.space/companies/medical-developments-international/) ASX: MVP - [Botanix Pharmaceuticals](https://aibio.space/companies/botanix-pharmaceuticals/) ASX: BOT - [Mayne Pharma Group](https://aibio.space/companies/mayne-pharma/) ASX: MYX ### Also on ASX - [Holista Colltech](https://aibio.space/companies/holista-colltech/) HCT - [Algorae Pharmaceuticals](https://aibio.space/companies/algorae-pharmaceuticals/) 1AI - [Clinuvel Pharmaceuticals](https://aibio.space/companies/clinuvel-pharmaceuticals/) CUV - [Neurizon Therapeutics](https://aibio.space/companies/neurizon-therapeutics/) NUZ - [Ocean Sciences](https://aibio.space/companies/ocean-sciences/) OSS - [LTR Pharma](https://aibio.space/companies/ltr-pharma/) LTP ## What Immuron does Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for inflammatory mediated and infectious diseases. Its proprietary platform uses oral polyclonal immunoglobulins, which can target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces within the gastrointestinal tract. Its flagship product, Travelan, is sold in Australia, Canada and the United States, and in Australia it is indicated to reduce the risk of travelers' diarrhea. The company launched ProIBS in Australia in October 2025, an over-the-counter product for relief of symptoms of irritable bowel syndrome. Marketed product sales were A$7.7 million for fiscal year 2026, A$7.3 million for 2025 and A$4.9 million for 2024. Its two lead oral polyclonal antibody candidates are in clinical development for travelers' diarrhea and recurrent Clostridiodies difficile infection. The company also describes a collaboration on anti-infective programs with the U.S. Department of Defense and a strategy to broaden its polyclonal-based pipeline across several indications. | Product or program | What it is | Stage | |---|---|---| | Travelan | Oral polyclonal antibody product for travelers' diarrhea, sold in several countries | marketed | | ProIBS | Over-the-counter product for relief of irritable bowel syndrome symptoms | launched in Australia in October 2025 | | Lead oral polyclonal antibody candidates | Candidates for travelers' diarrhea and recurrent C. difficile infection | clinical development | Summarised from the company's [20-F filed Sep 24, 2026](https://www.sec.gov/Archives/edgar/data/1660046/000121390026102838/ea0305398-20f_immuron.htm). ## Questions about Immuron Has Immuron raised money recently? Our latest story on this, dated Dec 4, 2025: "Immuron to issue 45,472,000 shares at AUD 0.07910 in placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/immuron-issue-45-472-000-shares-aud-0-07910-placement/). What is the ticker symbol of Immuron? Immuron Limited trades under the ticker IMC on ASX. Where is Immuron listed? Immuron Limited is listed on ASX. Our directory also records these other listings: GETTEX:ANW; NASDAQ:IMRN. What is the SEC CIK of Immuron? The SEC Central Index Key (CIK) for Immuron Limited is 1660046. Its filings are on SEC EDGAR. How many shares does Immuron have outstanding? 322,848,081 shares as of 2026-06-30, per the cover page of its 20-F filed 2026-09-24. Which country or territory is Immuron listed under? Our directory records Immuron Limited under Australia. What does Immuron do? Our directory classifies Immuron Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Immuron? The ISIN recorded for Immuron Limited is AU000000IMC7. Does aibio.space cover Immuron? aibio.space lists Immuron Limited among 2,820 public biotech companies and publishes its news here as stories appear. Where is Immuron incorporated? SEC records list its state or country of incorporation as C3. What does Immuron develop? Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for inflammatory mediated and infectious diseases. Its proprietary platform uses oral polyclonal immunoglobulins, which can target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces within the gastrointestinal tract. What is Travelan from Immuron? Travelan: Oral polyclonal antibody product for travelers' diarrhea, sold in several countries Stage: marketed. What is ProIBS from Immuron? ProIBS: Over-the-counter product for relief of irritable bowel syndrome symptoms Stage: launched in Australia in October 2025. What is the latest Immuron (IMC) stock news? Our latest story on Immuron, dated Dec 4, 2025: "Immuron to issue 45,472,000 shares at AUD 0.07910 in placement". The 45,472,000 shares are sold to US investors through the company's at-the-market facility, according to a note in the filing. The filing names no lead manager or underwriter. [Source](https://aibio.space/news/immuron-issue-45-472-000-shares-aud-0-07910-placement/). Is Immuron a smaller reporting company? SEC records list Immuron Limited's filer category as: Non-accelerated filer. ## Investor discussion: Immuron Members talk about Immuron (IMC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Immuron, newest first. Each line links the filing it comes from. 1. 2025-12-04 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1660046/000121390025118055/ea026846501ex99-1_immuron.htm) 2. 2025-11-06 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1660046/000121390025106828/ea026430401ex99-1_immuron.htm) 3. 2025-10-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1660046/000121390025099709/ea026158201ex99-1_immuron.htm) 4. 2025-07-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1660046/000121390025064884/ea024931401ex99-1_immuron.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open ASX:IMC on TradingView](https://www.tradingview.com/symbols/ASX-IMC/). ## SEC filings and registration - **SEC name**: Immuron Ltd - **CIK**: 1660046 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: IMRN (Nasdaq) - **State or country of incorporation**: C3 - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer - **Business address**: 62 LYGON STREET, CARLTON, VICTORIA, Australia, 3053 - **Phone**: 61 03 9824 5254 - **Shares outstanding**: 322,848,081 as of 2026-06-30 (20-F filed 2026-09-24) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1660046/000121390026111439/ea0309355-6k_immuron.htm) filed 2026-10-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1660046/000121390026110026/ea0308834-6k_immuron.htm) filed 2026-10-16 - [6-K](https://www.sec.gov/Archives/edgar/data/1660046/000121390026108742/ea0308406-6k_immuron.htm) filed 2026-10-13 - [20-F](https://www.sec.gov/Archives/edgar/data/1660046/000121390026102838/ea0305398-20f_immuron.htm) filed 2026-09-24 - [6-K](https://www.sec.gov/Archives/edgar/data/1660046/000121390026102804/ea0306529-6k_immuron.htm) filed 2026-09-24 - [6-K](https://www.sec.gov/Archives/edgar/data/1660046/000121390026101907/ea0306168-6k_immuron.htm) filed 2026-09-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1660046/000121390026097357/ea0304669-6k_immuron.htm) filed 2026-09-04 - [6-K](https://www.sec.gov/Archives/edgar/data/1660046/000121390026094657/ea0303772-6k_immuron.htm) filed 2026-08-28 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001660046), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Immuron Limited is a public biotech or pharmaceutical company listed on ASX under the ticker IMC, recorded under Australia. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Immuron Limited - **Ticker**: IMC - **Listing**: ASX - **Country or territory**: Australia - **Business scope**: Pharmaceuticals: Major - **ISIN**: AU000000IMC7 - **Other listed symbols**: GETTEX:ANW; NASDAQ:IMRN - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/ASX-IMC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/immuron/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Immuron (IMC) news: offering", 2026-10-31, https://aibio.space/companies/immuron/